In this Health Kick Podcast, Tim Boreham speaks with Paul de Souza, medical oncologist and co-founder of private drug developer ... Read More The post Health Kick Podcast: Filamon’s bold push against ...

B7-33 is a synthetic peptide derived from the relaxin protein family, specifically designed to interact with the relaxin ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple disease targets.

The story of the “Pharaoh’s Curse” haunted archaeologists for hundreds of years. It started with the excavation of King Tutankhamun’s tomb in 1922 and continued with the mysterious deaths of teams in ...

The selective and efficient capture of phosphopeptides is critical for comprehensive and in-depth phosphoproteome analysis. Here we report a new switchable two-dimensional (2D) supramolecular polymer ...

In the historic period, the growth can be attributed to the increasing prevalence of chronic diseases, heightening demand for targeted therapies, advancements in drug delivery systems and enhanced ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

UNP to receive a double digit million dollar upfront payment, near-term payments and up to approximately $1.5B in potential milestone payments plus ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...